Pulmonary Hypertension

Pharma

Merck's Winrevair cuts death, morbidity risk by 76%

Merck revealed data from a phase 3 study of Winrevair, which showed it reduced the risk of all-cause death, lung transplant or hospitalization by 76%.

Kevin Dunleavy Mar 31, 2025 10:00am

Ferrer calls out shortcomings of pulmonary hypertension pathways

Nov 20, 2024 2:15pm

FDA signs off on Merck’s potential blockbuster Winrevair for PAH

Mar 26, 2024 5:11pm

J&J dumps Opsumit trial upon pulmonary hypertension flop

Sep 7, 2023 11:03am

Janssen rounds out final live talk of 2022 for PH nurses

Dec 7, 2022 10:31am

J&J hosts educational talks online for PA nurses

May 20, 2022 8:35am